Day 1 | Day 2
Wednesday, March 14
7:15 am Morning Coffee
8:40 Chairperson’s Remarks
Sean Ekins, Ph.D., Collaborations Director, Collaborative Drug Discovery, Inc.
8:45 Combination Therapy for Rescuing Targeted Erlotinib Therapy in Oral Cancers: From in silico Models to Clinical Trial
Yves A. Lussier, M.D., Professor of Medicine and Engineering; Director, Institute for Interventional Health Informatics, University of Illinois at Chicago
9:15 Synopsis of Breakout Discussions
9:35 Systems and Chemical Biology Approaches and Tools for Faster‐to‐Market Drug Repositioning
Stephen Wong, Ph.D., P.E., Founding Chairman for Department of Systems Medicine and Bioengineering, The Methodist Hospital Research Institute; John S Dunn Distinguished Endowed Chair in Biomedical Engineering, The Methodist Hospital; Director, NCI Center for Modeling Cancer Development
10:05 Networking Coffee Break in the Exhibit Hall with Poster Viewing
10:45 Striking Gold: Pre-Clinical and Clinical Development of Auranofin for Relapsed Lymphocytic Leukemia
G. Sitta Sittampalam, Ph.D., Senior Scientific Officer, Therapies for Rare & Neglected Diseases and the Learning Collaborative, NIH Center for Translational Therapeutics, National Institutes of Health
In this presentation we will discuss the NIH Chemical Genomics Center (NCGC) Pharmaceutical Collection of approved drugs, and its application in repositioning auranofin for the treatment of relapsed CLL, progressing from screens of patient samples to the clinic in 18 months.
11:15 In silico Repositioning of Approved Drugs and Collaboration for Rare and Neglected Diseases
Sean Ekins, Ph.D., Collaborations Director, Collaborative Drug Discovery, Inc.
11:45 Panel Discussion: Turning Off-Target into “On” Target Drugs – Lessons to be Learned
12:15 pm End of Conference
Day 1 | Day 2